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ABSTRACT
Depression has become the fourth leading case for mortality and morbidity in the world.
It is a leading cause of disability worldwide and is a major contributor to the overall global
burden of disease. Current treatments of depression are inadequate, and the progress in
understanding the neurobiology of depression is slow. The first generation antidepressants like
monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) have shown to
possess a lot of side effects. Hydrazide-based monoamine oxidase inhibitors are known to result
in acute hypertensive crises and hepatotoxicity, as well as to interact with many foods and
biogenic amine drugs. Tricyclic antidepressants are known to associate with emotional blunting,
confusion, hypersensitivity, hypotension, and sometimes irregular heart rhythms. Research
efforts to discover other novel heterocycles that possess antidepressant activity have been
intensified recently. One of such discoveries is pyrazole compounds, and their antidepressant
activity has been shown to be very promising. Green chemistry was taken into consideration
while selecting the bases, catalysts, and solvent mediums for the reactions. The current synthetic
methods to access highly functional pyrazoles and the diversity of the chemical starting materials
to synthesize pyrazoles are limited. Therefore, this study was aimed at developing a method to
synthesize functional pyrazoles by using greener starting materials like dibromoalkene and
hydrazides.
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Chapter 1
Introduction
1.1 Trends in Depression
An “epidemic” of depression as a disease of modernity has been frequently claimed
[1],[2],[3]

. The high prevalence and enormous personal and economic disease burden highlight a

global health challenge of the 21st century [4] [5] [6].
Fundamentally, depression stands for a serious and common disorder which includes
symptoms like feeling of sadness, anhedonia, hopelessness, guilt and pessimism, weight loss or
gain, tiredness, changes in sleeping routine, suicidal ideation as well as cognitive impairment [1].
Patients may also present with other contradictory symptoms such as lethargy, insomnia, social
withdrawal, and sexual dysfunction among a range of others

[14]

. Despite the advances in

diagnosis, recognition, and categorisation of depression the underlying causes of the symptoms
are poorly understood

[14]

. Depression can affect mental, emotional, and physical health.

However, so far, clinical studies have shown that the treatment efficacy of depression is not
satisfactory [38].
Depression in recent years has become a major public health issue, and the fourth case of
morbidity and mortality, affecting up to 20% of the world’s population

[2] [9].

According to the

world health organization (WHO), over 300 million people were estimated to be affected by
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depression globally in 2015, an increase of 18.4% since 2005

[21]

. In addition to the societal

burden, depression contributes approximately $44 billion in lost productivity annually in the
United States [10].

Figure 1.1: Depression trend in the USA from 2005-2015 (22). The prevalence of past-year
depression increased significantly from 2005 to 2015.
Major depressive disorder (MDD) is a chronic and progressive mental disorder with
heterogeneous etiology and symptoms and a high incidence of recurrence. MDD is a major risk
factor for suicide, which is the tenth leading cause of death globally and is comorbid with several
chronic diseases, including heart disease, stroke, diabetes, and cancer. It is estimated that about
10% of the US population are being treated with antidepressants for either depression or related
disorders [41].
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Suicide is an important public health issue involving psychological, biological, and
societal factors [46],[47]. According to the Center for Disease Contol and prevention (CDC), after a
period of nearly consistent decline in suicide rates in the United States from 1986 through 1999,
suicide rates have increased almost steadily from 1999 through 2014 [47]. In 2016, suicide ranked
as the 10th leading cause of death among Americans. It is the second leading cause of death for
those under the age of 35 [44]. Depression and suicide are linked, with an estimate that up to 60%
of people who commit suicide have major depression [45].
Because of minimal resources and effective treatment methods, the diagnosis and
treatment rate of depression is generally low. Identifying the risk factors of depression, early
prevention and intervention can effectively delay the occurrence and development of depression.
The risk factors of depression include physiological, psychological and social factors, among
which the relationship between physiological factors and the occurrence of depression has been
widely recognized, while the psychological and social factors are closely related to the
occurrence of depression, and the conclusion is controversial [38].

1.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants
Tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOIs) were the
first-generation antidepressants introduced in the late 1950s
amphetamines were commonly used as antidepressants

[3],[4]

. Before the 1950s, opioids and

[54],[55]

. Iproniazid, a monoamine oxidase

inhibitor (MAOI) and imipramine, a tricyclic antidepressant (TCA) were the first two
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widespread antidepressant drugs in clinical use [23] [24]. In 1951, Irving Selikoff and Edward H.
Robitzek, working out of Sea View Hospital on Staten Island, began clinical trials on two new
anti-tuberculosis agents developed by Hoffman-LaRoche, isoniazid and iproniazid [50].
In 1952, a few psychiatrists tried these drugs on their patients and they reported that iproniazid
improved depression in two-thirds of their patients and coined the term antidepressant to refer to
its action

[51]

. The mode of antidepressant action of iproniazid is still unclear. It is speculated that

its effect is due to the inhibition of diamine oxidase, coupled with a weak inhibition of
monoamine oxidase A [52]. Iproniazid and imipramine made two fundamental contributions to the
development of psychiatry: one of a social-health nature, consisting in an authentic change in the
psychiatric care of depressive patients; and the other of a purely pharmacological nature, since
these agents have constituted an indispensable research tool for neurobiology and
psychopharmacology, permitting, among other things, the postulation of the first etiopathogenic
hypotheses of depressive disorders

[48]

. Iproniazid remained relatively obscure until Nathan S.

Kline, the influential head of research at Rockland State Hospital, began to popularize it in the
medical and popular press as a "psychic energizer"

[56],[57]

. Roche put a significant marketing

effort behind iproniazid. Its sales grew until it was recalled in 1961, due to reports of lethal
hepatotoxicity [56].
They were subsequently shown to increase the serotonin or norepinephrine
neurotransmission, suggesting that their antidepressant actions could be attributed to this effect
and by extension that depression was due to deficiencies in monoamine neurotransmission [11] [12]
[13]

.
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The early theories of the pathogenesis of depression consisted of the monoamine theory
which primarily hypothesized that depression could be a result of decreased availability of
monoamine neurotransmitters like serotonin and noradrenaline in the central nervous system [15].
This hypothesis is based on an unanticipated discovery that drugs which tend to increase the
monoamine availability are effective antidepressants [14]. Selective serotonin reuptake inhibitors
(SSRIs) noradrenaline reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors (SNRIs)
and dopamine-noradrenaline reuptake inhibitors (DNRIs) were enhanced with fewer adverse
effects than traditional antidepressants

[5] [6].

Despite various developments in the field of

antidepressants, the clinical use of first-generation drugs were restricted because of various
adverse effects and a response in less than 50% of patients [7] [8].

1.2.1 Examples of TCAs and MAOIs
First generation TCAs (1-5) including desipramine (1) and imipramine (2) and MAOIs
including tranylcypromine (6) were introduced in the 1950s after being serendipitously
discovered to be effective in treating depression (Figure 1.2)

[39]

. They were later shown to

increase monoaminergic neurotransmission either by blocking the reuptake of monoamine
neurotransmitters or by preventing their metabolism. These drugs are now largely restricted to
use in severe or refractory depression due to poor tolerance. While TCAs are known to cause
cardiovascular, anticholinergic and sedative side effects due to the off-target pharmacology (for
example, adrenergic, histaminergic, and muscarinic receptors), MAOIs produce dietary and
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drug–drug interactions that can be lethal [40].

Figure 1.2. Select examples of TCAs and MAOIs as first-generation antidepressants [2].

1.3 Side Effect of MAOI and TCA
1.3.1 Side Effect of MAOIs
1. Hypertensive crisis:
People consuming MAOIs generally need to change their diets to limit food and
beverage intake that contain tyramine (TYR), which is mainly found in products such as
cheese, soy sauce, and salami

[25]

. Tyramine being a potent releaser of norepinephrine

works to elevate the blood pressure. Monoamine oxidase-A acts to destroy
norepinephrine to keep it in balance. When MAO-A inhibition takes place in the presence
of tyramine, the increase in norepinephrine induced by tyramine is not countered by its
destruction via MAOA, and consequently the combination can lead to a very large
accumulation of norepinephrine. Such a great norepinephrine accumulation can lead to
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excessive stimulation of postsynaptic adrenergic receptors, and therefore dangerous
vasoconstriction and elevation of blood pressure. Some blood pressure elevations can be
very large, sudden, and dramatic, causing a condition known as a hypertensive crisis [26].
2. Drug Interaction:
MAOIs can potentially interact with over-the-counter drugs, prescription, or
illegally obtained medications[28]. Moreover, MAOIs can interact with tobacco-containing
products (e.g. cigarettes) and may potentiate the effects of certain compounds in tobacco
[29] [30]

.

3. Withdrawal:
MAOIs are known to produce dependency-producing effects, the most notable
being a discontinuation syndrome. This occurs if MAOIs are discontinued abruptly or too
rapidly [27].

1.3.2 Side Effect of TCAs
One of the main reasons for the massive shift from TCAs, which formerly dominated the
pharmacotherapy of depression are the adverse effect burden of TCAs and their lethality in
overdose [33]. The side effects of TCAs may be related to the antimuscarinic properties, these side
effects are relatively common and may include dry mouth, blurry vision, emotional blunting,
confusion, hypersensitivity, hypotension, and sometimes irregular heart rhythms

[31]

. Similar to

MAOIs, TCAs can also produce discontinuation syndrome if they are discontinued abruptly or
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too rapidly [32].

1.4 Pyrazoles
Pyrazoles are the five-membered heterocycles that constitute an useful class in organic
synthesis. They are one of the most studied groups in the azole family. Pyrazole, which has two
nitrogen atoms and aromatic character, provides diverse functionality and stereochemical
complexity in a five-membered ring structure [37]. Over the past years, a huge variety of synthesis
methods and analogues have been reported

[34]

. The presence of the pyrazole nucleus in different

structures has led to diverse applications in different areas such as technology, medicine, and
agriculture. In particular, pyrazoles have been recently used as antidepressants [35] [36]. Nowadays,
pyrazole systems, as biomolecules, have attracted more attention due to their interesting
pharmacological properties. In particular, they are described as inhibitors of protein glycation,
antibacterial,

antifungal,

anticancer,

antioxidant as well as antiviral agents

antidepressant, antiinflammatory,

anti-tuberculosis,

[49]

. This heterocycle can be traced in a number of

well-established drugs belonging to different categories with diverse therapeutic activities [34].
Pyrazole is a π-excess aromatic heterocycle. Electrophilic substitution reactions occur
preferentially at position 4 and nucleophilic attacks at positions 3 and 5. The pyrazoles diversely
substituted by aromatic and heteroaromatic groups possess numerous biological activities, which
makes them particularly interesting. The various access routes to the pyrazole nucleus have
undergone numerous modifications since the first syntheses described by Knorr [50].
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Figure 1.3: Pyrazole structure

Figure 1.4: Some of the pyrazole containing drugs.
As a result, a large number of pyrazoles have been obtained and some of them gained
application on the clinical level. These compounds have diverse biological CNS activity like
antiepileptic, antidepressant, etc. Moreover, inhibition of enzyme monoamine oxidase (MAO)
results in increased levels of biological amine (norepinephrine, dopamine and serotonin) in
neurons of the central nervous system and in various other tissues. There have been many reports
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on the antidepressant/MAO-inhibiting activity of pyrazoles

[42]

. Both bromine and amine are

known to increase the functionality of pyrazoles. The bromine substituent can take part in
halogen bonding which allows the possibility of various different reactions to take place.
Chemically speaking, the current synthetic methods to access highly functional pyrazoles and the
diversity of the chemical starting materials are limited. Thus, this study was primarily focused on
synthetic methods to develop highly functional pyrazoles. The synthesis of pyrazole was carried
out using hydrazines and dibromoalkenes by varying the condition mediums in order to elucidate
the products. The figure 1.5 shows a proposed mechanism of the reaction.

Figure 1.5: Two possible reaction mechanisms
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1.5 Green Chemistry
The most important goals of sustainable development are reducing the adverse
consequences of the substances that we use and generate. The role of chemistry is essential in
ensuring that our next generation of chemicals, materials, and energy is more sustainable than the
current generation[61]. Worldwide demand for environmentally friendly chemical processes and
products requires the development of novel and cost-effective approaches to pollution
prevention. One of the most attractive concepts in chemistry for sustainability is Green
Chemistry, which is the utilization of a set of principles that reduces or eliminates the use or
generation of hazardous substances in the design, manufacture, and applications of chemical
products[62]. Early pioneers in green chemistry included Trost (who developed the atom economy
principle) and Sheldon (who developed the E-Factor)[63][64]. These measures were introduced to
encourage the use of more sustainable chemistry and provide some benchmarking data to
encourage scientists to aspire to more benign synthesis. Later, green chemistry became
formalised by the publication by Warner and Anastas of a holistic set of principles designed to
raise awareness of the safe, environmentally sensitive and sustainable practice of chemistry [65].
Selecting the right acids or bases for a particular chemical transformation is influenced by
a number of factors, including environmental, health and safety effects, reagent strength,
solubility, boiling point, ease of removal and/or recovery, and ease of handling. These constraints
may not always give rise to a variety of choices, but if there are multiple options, sustainability
assessments can be consulted. Medicinal Chemistry timelines can sometimes hinder
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consideration of sustainability, but as projects progress, consulting these guides can be helpful
before larger investments are made into the original Medicinal Chemistry routes and reagents [66].
When acids or bases are used as solvents, other factors such as waste handling and life cycle
assessment may need additional consideration. Solvent guides published by various
pharmaceutical companies can help evaluate the possible choices. Acids and bases as potential
salt partners for in vivo experiments will have to undergo more rigorous health assessments,
however the inclusion of information as to which acids and bases are generally recognized as
safe (GRAS) by the US Food and Drug Administration as of March 2014 may assist in some
decision making. Individual pKa values are a key consideration when selecting acids and bases.
Including pKa data in the acid/base guides increases utility and may help encourage chemists to
consult these guides, and related reagent guides [66]. In addition to their sustainability advantages,
greener acids and bases often have additional benefits. Commonly used reactions found in the
Medicinal Chemistry literature may have significant issues when employed on large scale.
Choosing more sustainable conditions by first intent in Medicinal Chemistry can result in safer
reaction conditions, less hazardous waste, and significant time savings during subsequent scale
up campaigns.
The principles of atom economy and step economy are historically the underpinnings of
efficiency critical to process development and manufacturing in the pharmaceutical industry and
have increasingly been moving to the forefront of strategic considerations for practicing
medicinal chemists in drug discovery efforts [68].
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Chapter 2
Experimental
2.1 Synthetic Step A: Synthesis of Dibromoalkenes

Figure 2.1: The synthesis of 1-(2,2-dibromovinyl)-4-methoxybenzene

To a stirred solution of 4-methoxybenzaldehyde (525 mg, 3.5 mmol) and carbon
tetrabromide (2.317 g, 7 mmol) in anhydrous dichloromethane (10 mL) was added
triphenylphosphine (3.654 g, 14 mmol, 4 equiv) in portions over a period of 20 mins at 0 °C
temperature under inert atmosphere. The reaction mixture was turned brown that was allowed to
stir at 0 °C temperature for 2 h. After completion of reaction (monitored by TLC), reaction
mixture was quenched with water (15 mL). The reaction mixture was extracted with
dichloromethane (2 x 20 mL); organic layers were washed with brine (10 mL). The organic
layers were dried over anhydrous Na2SO4; solvent was evaporated under reduced pressure to
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afford a crude residue. The crude was purified on SiO2 (60-120 mesh) column using
Hexanes/EtOAc (95:5) as eluents to afford the analytically pure product as pale yellow solid [59].

2.2 Synthetic Step B: Synthesis of Pyrazoles
To a stirred solution of 1-(2,2-dibromovinyl)-4-methoxybenzene (50 mg, 0.17 mmol)
and 4-methylbenzohydrazide (31 mg, 0.26 mmol) in methanol ( 1.7 mL) was added lanthanide
catalysts along with DIPEA (2 eq, 0.34 mmol) as a base. The reaction mixture was carried at
room temperature for 16 hours and TLC was checked every 30 minutes for the first 3 hours to
determine when the reaction completed. The reaction mixture was extracted with ethyl acetate
(EtOAc) (2 x 20 mL); organic layers were washed with brine (10 mL). The organic layers were
dried over anhydrous Na2SO4; solvent was evaporated under reduced pressure to afford a crude
residue. The crude was purified on SiO2 (60-120 mesh) column using Hexanes/EtOAc as eluents
to afford the analytically pure product. Many further reactions were carried out by changing the
lanthanide catalysts, bases, solvent mediums, temperatures, and the dibromo benzene starting
material in order to successfully characterize the product.

2.3 Chromatographic Purification
Thin layer chromatography (TLC) along with a UV light source was used to monitor the
reaction progress with references to the starting materials and products using aluminum plates
coated with silica gel and a phosphor. Moreover, column chromatography using silica gel
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performed using appropriate mobile phase solvents and 60-120 mesh. Fractions were then
collected and examined by comparing the samples from test tubes to the crude and reference
materials through TLC.

2.4 NMR Analysis
The NMR data was obtained by using a Bruker AscendTM 400 MHz NMR spectrometer.
The samples were prepared using either deuterated chloroform (d- CDCl3), deuterated methanol
(d-MeOH), or deuterated acetone depending on solubility of the sample. (1-H) Proton and (13-C)
carbon spectras were obtained. Mestrelab (MNova) software was used in order to analyze the
data obtained. The baseline correction, peak picking, and integration functions were utilized.
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Chapter 3
Results and Discussion
In order to characterize the product various different conditions were tried. The solvent
and base were chosen to be MeOH and DIPEA respectively because of their greenness. Along
with that, the starting materials readily dissolved in methanol and the high pKa of DIPEA made
it a good choice for base[60]. The lanthanides act as Lewis acid for this reaction and they also
possess green properties. The lanthanides, temperatures, and concentration of the starting
materials were varied. The reactions 3.1.1-3.1.4 were carried out at room temperature with 0.1 M
concentration. The concentration of the starting material was then increased to 0.5 M upon
observing no change. The reaction 3.1.9 was heated under reflux in order to speed up the
reaction and help to overcome the activation energy.
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Reaction

Solvent

Base

Lewis
Acid

Conc

Temp

3.1.1

MeOH

DIPEA (2eq)

Yb(OTf)3

0.1M

Room Temp

3.1.2

MeOH

DIPEA (2eq)

Gd(OTf)3

0.1M

Room Temp

3.1.3

MeOH

DIPEA (2eq)

Zn(OTf)3

0.1M

Room Temp

3.1.4

MeOH

DIPEA (2eq)

In(OTf)3

0.1M

Room Temp

3.15

MeOH

DIPEA (2eq)

Yb(OTf)3

0.5M

Room Temp

3.1.6

MeOH

DIPEA (2eq)

Gd(OTf)3

0.5M

Room Temp

3.1.7

MeOH

DIPEA (2eq)

Zn(OTf)3

0.5M

Room Temp

3.1.8

MeOH

DIPEA (2eq)

In(OTf)3

0.5M

Room Temp

3.1.9

MeOH

DIPEA (2eq)

Yb(OTf)3

0.5M

Heat under reflux

Table 3.1: Summary of the reaction conditions used while varying the lewis acid
The solvent system was varied upon observing no change and the reaction 3.2.1-3.2.6
was tried at room temperature, reflux, and 0℃. Moreover, reactions 3.2.5 and 3.2.6 were tried
with DIPEA as the solvent in order to increase the basicity and observe the changes in the
reaction. The reaction 3.2.4 was tried with tetrahydrofuran (THF) because of its moderate polar
aprotic solvent nature which is based on its cyclic structure that locks in its polarity. It was
chosen as opposed to MeOH which is polar protic in nature to observe if it would have any effect
25

on the reaction.
#

Solvent

Base

Lewis
Acid

Conc

Temp

3.2.1

MeOH.
𝐻2𝑂

DIPEA
(2eq)

In(OTf)3

0.5M

Heat under reflux

3.2.2

DCM

DIPEA
(2 eq)

In(OTf)3

0.5M

Room Temp

3.2.3

Ethanol

DIPEA
(2 eq)

In(OTf)3

0.5M

0℃

3.2.4

THF

DIPEA
(2 eq)

In(OTf)3

0.5M

0℃

3.2.5

DIPEA

DIPEA

Gd(OTf)3

0.5M

Room Temp

3.2.6

DIPEA

DIPEA

Gd(OTf)3

0.5M

Heat under reflux

Table 3.2: Summary of the reaction conditions used while varying the solvent system.
The variation of solvent mediums did not have any significant effect on the reaction.
Therefore, bases were varied and different bases with varying pKa values were examined.
1,8-Diazabicycloundec-7-ene (DBU) with a pKa of 13.5 was used to carry out the reaction 3.3.1
because it is a non nucleophilic base. Moreover, a strong base such as Lithium bis(trimethylsilyl)
amide (LiHMDS) with a pKa of ~26 was used in reaction 3.3.4 to examine its effect on the
reaction.
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#

Solvent

Base

Lewis
Acid

Conc

Temp

3.3.1 MeOH

DBU (2eq)

In(OTf)3

0.5M

Heat under reflux

3.3.2 MeOH

NaOH (2eq)

In(OTf)3

0.5M

Heat under reflux

3.3.3 EtOH

Cs2CO2
(2 eq)

Gd(OTf)3

0.5M

Heat under reflux

3.3.4 THF

LiHMDS

Gd(OTf)3

0.5M

Dry Ice

Table 3.3: Summary of the reaction conditions used while varying the bases.
The expected product was not obtained even after trying the above mentioned reaction
conditions. Therefore, we hypothesize that the 1-(2,2-dibromovinyl)-4-methoxybenzene
compound is not reactive enough in order to react with the 4-methylbenzohydrazide starting
material and the catalyst under any given conditions. This could be because the starting material
is not a good nucleophile-electrophile combination. Hence, a different starting material was used
in place of the 1-(2,2-dibromovinyl)-4-methoxy benzene compound. A few reactions were set up
with 4-bromo-1-butyne as the starting material along with 4-methylbenzohydrazide. This
compound was chosen because it is a good leaving group in presence of a strong base. Copper
iodide was chosen as the catalyst because of its proven results in catalysing reactions that involve
alkynes and azides in click chemistry.
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#

Solvent

Base

Lewis Acid

Conc

Temp

3.4.1 MeOH

DIPEA (2eq)

Gd(OTf)3 +CuI 0.5M

Heat under reflux

3.4.2 MeOH

DIPEA (2eq)

CuI

0.5M

Heat under reflux

Table 3.4: Summary of the reaction conditions used with 4-bromo-1-butyne as the starting
material
The table 3.4 shows a summary of the two reaction conditions. The reaction 3.4.2 looks
promising as a new spot was observed on the TLC plate but a clean NMR spectra could not be
obtained. In future, different ways of purifying the compound should be explored in order to
retrieve a pure product. Moreover, different catalysts can be explored in order to increase the
efficiency of the reaction.
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Chapter 4
Conclusion
In conclusion, the multi-substituted pyrazoles are highly functional compounds with
widespread applications. The current methods to synthesize pyrazoles are limited. Therefore, this
study was aimed at developing a method to obtain multi-substituted pyrazoles from diverse
starting materials using greener bases and catalysts. We were able to eliminate the reaction
conditions which did not work and narrow down the reaction conditions which have a potential
to form the proposed product. Further investigation regarding the starting materials, catalysts,
bases, and the solvent mediums is necessary to conclude a reaction method to obtain the
proposed product.
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Figure S.1: Proton NMR of 1-(2,2-dibromovinyl)-4-methoxybenzene
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Figure S.2: Carbon NMR of 1-(2,2-dibromovinyl)-4-methoxybenzene
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Figure S.3: Proton NMR of 4-methylbenzohydrazide
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Figure S.4: Proton NMR of 4-methylbenzohydrazide
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Figure S.5: Proton NMR of 1-bromo-4-butyne
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Figure S.6: Carbon NMR of 1-bromo-4-butyne
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